Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)Shirish M. Gadgeel, Karen Kelly, Timothy F. Burns et al.|Clinical Cancer Research|2023Cited by 21
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C <i>KRAS</i> mutation positive (+) recurrent non-small cell lung cancer (NSCLC).Shirish M. Gadgeel, Karen Kelly, Jieling Miao et al.|Journal of Clinical Oncology|2019Cited by 17
1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900AJonathan W. Riess, Karen Kelly, Jieling Miao et al.|Annals of Oncology|2024Cited by 2